{
    "ticker": "ACRV",
    "name": "Acrivon Therapeutics, Inc.",
    "description": "Acrivon Therapeutics, Inc. is an innovative biotechnology company dedicated to developing targeted therapeutics that leverage its proprietary Acrivon OncoSignature\u2122 technology. Founded in 2020, Acrivon aims to transform cancer treatment by personalizing therapies based on the unique molecular profiles of individual tumors. The company's focus is on advancing precision medicine in oncology, allowing for more effective treatment options tailored to the patient's specific cancer characteristics. Acrivon\u2019s pipeline includes multiple drug candidates designed to improve response rates in patients with various types of cancer, including those resistant to conventional therapies. The company's commitment to scientific excellence and patient-centric focus is reflected in its collaborations with leading academic institutions and biotech partners, ensuring that its research and development efforts are at the forefront of cancer treatment innovation. With a strong emphasis on clinical validation and biomarker-driven approaches, Acrivon is positioned to make a significant impact on the future of cancer therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2020",
    "website": "https://www.acrivon.com",
    "ceo": "Gordon L. Binder",
    "social_media": {
        "twitter": "https://twitter.com/AcrivonThera",
        "linkedin": "https://www.linkedin.com/company/acrivon-therapeutics"
    },
    "investor_relations": "https://www.acrivon.com/investors",
    "key_executives": [
        {
            "name": "Gordon L. Binder",
            "position": "CEO"
        },
        {
            "name": "Rita L. D'Agnese",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Drug Candidates",
            "products": [
                "ACR-368",
                "ACR-391"
            ]
        }
    ],
    "seo": {
        "meta_title": "Acrivon Therapeutics, Inc. | Precision Oncology",
        "meta_description": "Explore Acrivon Therapeutics, Inc., a biotechnology company focused on precision oncology through targeted therapeutics and personalized treatment strategies.",
        "keywords": [
            "Acrivon",
            "Biotechnology",
            "Precision Medicine",
            "Oncology",
            "Cancer Treatment",
            "Acrivon OncoSignature"
        ]
    },
    "faq": [
        {
            "question": "What is Acrivon Therapeutics known for?",
            "answer": "Acrivon Therapeutics is known for developing targeted therapeutics in oncology using its proprietary Acrivon OncoSignature technology."
        },
        {
            "question": "Who is the CEO of Acrivon Therapeutics?",
            "answer": "Gordon L. Binder is the CEO of Acrivon Therapeutics, Inc."
        },
        {
            "question": "Where is Acrivon headquartered?",
            "answer": "Acrivon is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Acrivon's main products?",
            "answer": "Acrivon's main products include oncology drug candidates such as ACR-368 and ACR-391."
        },
        {
            "question": "When was Acrivon founded?",
            "answer": "Acrivon was founded in 2020."
        }
    ],
    "competitors": [
        "MRNA",
        "BMY",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "NVAX",
        "GILD",
        "CELG",
        "VRTX"
    ]
}